

Anti-Complement C5 Reference Antibody (ravulizumab)

Recombinant Antibody Catalog # APR10082

Specification

Anti-Complement C5 Reference Antibody (ravulizumab) - Product Information

Application
Primary Accession
Reactivity
Clonality
Isotype
Calculated MW

P01031 Cynomolgus, Human, Mouse Monoclonal IgG2SA

FC, E, FTA

145.8 KDa

Anti-Complement C5 Reference Antibody (ravulizumab) - Additional Information

Target/Specificity Complement C5

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Storage

-80°C for 2 years under sterile conditions -20°C for 1 year under sterile conditions Avoid repeated freeze-thaw cycles.

Anti-Complement C5 Reference Antibody (ravulizumab) - Protein Information

Name C5

Synonyms CPAMD4

Function

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

Cellular Location

Secreted.




Anti-Complement C5 Reference Antibody (ravulizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

Anti-Complement C5 Reference Antibody (ravulizumab) - Images



Anti-Complement C5 Reference Antibody (ravulizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Complement C5 Reference Antibody (ravulizumab)is more than 98.96% ,determined by SEC-HPLC.



